The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Arthritis Drug Anakinra Shows Promise in COVID-19

Arthritis Drug Anakinra Shows Promise in COVID-19

May 12, 2020 • By Megan Brooks

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Treatment with the interleukin-1 blocker anakinra appears to improve respiratory symptoms and reduced signs of cytokine storm in nearly three-quarters of patients with acute respiratory distress and cytokine release syndrome from COVID-19 in a small retrospective study from Italy.

You Might Also Like
  • Sarilumab Trial Data Shows It May Only Help Critical COVID-19 Patients
  • Tocilizumab Begins Clinical Trial for COVID-19
  • Hydroxychloroquine for COVID-19 Fails Another Test
Explore This Issue
June 2020

“Our study is the first to suggest that a high dose of the arthritis drug anakinra may be able to block the overreaction of the immune system caused by COVID-19. The results are interesting and the drug deserves controlled testing in large randomized trials,” Dr. Giulio Cavalli of San Raffaele Hospital, Milan, says in a statement.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study, published in The Lancet Rheumatology, included consecutive adults with COVID-19, moderate-to-severe acute respiratory distress syndrome (ARDS) and hyperinflammation (defined as a serum C-reactive protein at least 100 mg/L, ferritin at least 900 ng/mL, or both).1

The researchers compared clinical results in 29 patients who received high-dose intravenous anakinra, non-invasive ventilation and standard treatment with hydroxychloroquine and lopinavir/ritonavir with that of 16 patients who received non-invasive ventilation and standard treatment only.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At 21 days, 21 (72%) of 29 patients treated with anakinra experienced reductions in serum C-reactive protein and progressive improvements in respiratory function; five (17%) required mechanical ventilation and three (10%) died.

In contrast, only eight (50%) of 16 patients who did not receive anakinra showed respiratory improvement at 21 days; one (6%) required mechanical ventilation and seven (44%) died.

The 21-day survival rate was 90% with anakinra vs. 56% without (P=0.009). Mechanical-ventilation-free survival was 72% with anakinra vs. 50% without (P=0.15).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Bacteremia occurred in four (14%) patients receiving anakinra and two (13%) receiving standard treatment only. Stopping anakinra did not result in inflammatory relapses. Causes of death in both groups were pulmonary thromboembolism, respiratory insufficiency and multiorgan failure.

In an email to Reuters Health, Dr. Cavalli says, “I believe that high-dose anakinra is a safe and potentially effective therapy, which is worth pursuing in the subgroup of severe patients with COVID-19 who develop hyper-inflammatory immune responses to the virus.”

In the statement, co-author Dr. Chiara Tassan Din, also with San Raffaele Hospital, notes that patients in the study were older (mean age: 62 years), severely ill and with underlying health conditions, placing them at high risk of dying from COVID-19.

“Administration of high-dose intravenous anakinra in these patients, who were managed outside of the ICU in a setting overwhelmed by the COVID-19 pandemic and with a shortage of ICU resources, appeared to dampen systemic inflammation and was associated with progressive improvement in respiratory function. This seems to have allowed us to postpone or avoid intubation in most patients. Based on our promising results, this approach may be considered irrespective of resource availability,” she says.

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: anakinra, coronavirus, COVID-19Issue: June 2020

You Might Also Like:
  • Sarilumab Trial Data Shows It May Only Help Critical COVID-19 Patients
  • Tocilizumab Begins Clinical Trial for COVID-19
  • Hydroxychloroquine for COVID-19 Fails Another Test
  • Hydroxychloroquine Tied to Increased Risk of Death in COVID-19 Patients

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.